Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
Farmers Insurance
Cantor Fitzgerald
Cipla
Baxter
AstraZeneca
Teva
McKinsey

Generated: November 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 014399

« Back to Dashboard

NDA 014399 describes NORPRAMIN, which is a drug marketed by Us Pharm Holdings and is included in one NDA. It is available from three suppliers. Additional details are available on the NORPRAMIN profile page.

The generic ingredient in NORPRAMIN is desipramine hydrochloride. There are nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the desipramine hydrochloride profile page.
Summary for 014399
Tradename:NORPRAMIN
Applicant:Us Pharm Holdings
Ingredient:desipramine hydrochloride
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 014399
Medical Subject Heading (MeSH) Categories for 014399
Suppliers and Packaging for NDA: 014399
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399 NDA sanofi-aventis U.S. LLC 0068-0007 0068-0007-01 100 TABLET, SUGAR COATED in 1 BOTTLE (0068-0007-01)
NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399 NDA sanofi-aventis U.S. LLC 0068-0011 0068-0011-01 100 TABLET, SUGAR COATED in 1 BOTTLE (0068-0011-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 004

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength75MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Expired US Patents for NDA 014399

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-006 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-007 Feb 11, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-003 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-004 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-004 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-005 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Julphar
Cantor Fitzgerald
Chinese Patent Office
Mallinckrodt
McKinsey
Accenture
UBS
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.